Buy AB-PINACA crystal

Buy AB-PINACA crystal is a substance that was discovered in 2012 in Japan to be a part of artificial cannabis products.

It was first created as an analgesic drug by Pfizer in 2009.

AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for?9-THC in rat discrimination studies, while being 1.5x more potent.

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.

The synthetic cannabinoid AB-PINACA is typically marketed as a herbal smoking blend that simulates the effects of THC, the psychoactive ingredient in cannabis. As an alternative to illegal narcotics, synthetic cannabinoids are classified as new psychoactive compounds (NPS), which are uncontrolled compounds that have recently been available on the market.

Producers of synthetic cannabinoids alter the chemicals in designer medicines in response to prohibition, resulting in the development of new generations of synthetic pharmaceuticals like AB-PINACA. As a result, because the kind and concentration of the active ingredient might differ much between batches, there may be a higher chance of inadvertent overdose and serious mental health issues. Agitation, a fast heartbeat, disorientation, lightheadedness, and nausea are possible side effects. AB-PINACA

Buy AB-PINACA CRYSTAL

{Buy AB-PINACA CRYSTAL} is a strong agonist of both CB1 and CB2 receptors and a synthetic cannabinoid belonging to the aminoalkylindazole class. In the first half of 2014, 11% of all reports of synthetic cannabinoid drugs in the US were related to AB-PINACA, according to the NFLIS 2014 midyear report. This approved reference solution can be used in forensic analysis, urine drug testing, clinical toxicology, and synthetic cannabinoid testing procedures using LC/MS or GC/MS.

*Forensic Use Products Statement

Utilization in Forensic Devices are solely meant to be used in drug abuse testing for law enforcement.

Appropriate users of such devices include, for example, court systems, police departments, probation/parole offices, juvenile detention centers, prisons, jails, correction centers and other similar law enforcement entities, or laboratories or other establishments performing forensic testing for these entities.

Forensic Use Only devices are not designed, tested, developed, or labeled for use in other settings, such as clinical diagnostic or workplace settings.

Intended Use
The goal of the CEDIA® AB-PINACA test is to identify and quantify the parent compound and metabolites of AB-PINACA, AB-CHMINACA, and AB-FUBINACA at a 20 ng/mL threshold in human urine using a qualitative and semi-quantitative approach.

The assay offers a quick and easy way to identify synthetic cannabis chemicals and metabolites related to AB-PINACA in human urine. It is designed to be utilized in laboratory settings. In order to enable laboratories to establish quality control procedures or to determine an appropriate dilution of the specimen for confirmation by a confirmatory method like liquid chromatography/tandem mass spectrometry (LC-MS/MS), they employ the semi-quantitative mode for detection. Any substance of abuse test result should be interpreted with clinical and professional discretion, especially when using preliminary positive results.

Metabolite Analysis.
Intraperitoneal injections of 3 mg/kg AB-PINACA, 3 mg/kg AB-CHMINACA, or 100 mg/kg FUBIMINA were administered to 12 mice (n = 4 per medication). The mice were given injections, after which they were put in metabolism cages and their urine was collected for a full day. For analysis, urine from mice given the same dosage of the chemical was combined. Before analysis, samples were extracted using a salting-out liquid-liquid extraction technique.

The samples were vortexed and 50 µl of 5 M ammonium acetate was added as a salting out agent after 200 µl of acetonitrile had been added to 100 µL of urine. The samples were centrifuged for five minutes at 10,000 rcf after being vortexed. After removing the top aqueous layer and drying it at 40°C, 50 µl of mobile phase A was used to reconstitute it..

Discussion
Psychoactive cannabinoid agonists produce a characteristic profile of in vitro and in vivo pharmacological effects, including binding to and activating CB1 receptors, dose-dependent activity in a tetrad battery of tests in mice, and ?9-THC-like discriminative stimulus effects (Wiley and Martin, 2009).

See also

5F-AB-PINACA
5F-ADB
5F-AMB
5F-APINACA
5F-CUMYL-PINACA
AB-CHFUPYCA
AB-FUBINACA
AB-PICA
ADB-CHMINACA
ADB-FUBINACA
ADB-PINACA
ADBICA
APICA
APINACA
MDMB-CHMICA
PX-3